Accès aux molécules innovantes dans le traitement du cancer en France : le programme CLIP² |
|
Access to innovation drugs in cancer's treatment : the CLIP². |
|
Anémie et cancer : quelles perspectives d'amélioration de la prise en charge du patient résistant à l'érythropoïétine ? |
|
Antalgiques, anti-inflammatoires |
|
Antiarythmiques |
|
Antibactériens |
|
Anticancéreux |
|
Antidépresseurs & anxiolytiques |
|
Antidiabétiques oraux |
|
Antihypertenseurs |
|
Antiviraux |
|
Dialyse péritonéale : médicaments anti-infectieux |
|
Fonction rénale et cancer |
|
GPR neurologie, guide de prescription des médicaments chez le patient insuffisant rénal |
|
Hémostase |
|
Hypertension and proteinuria: a class-effect of antiangiogenic therapies. |
|
Hypolipémiants |
|
Immunosuppresseurs |
|
Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis |
|
Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study |
|
Insuffisance coronaire |
|
Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies. |
|
[Iron deficiency and anemia in oncology] |
|
[Kidney and cancer: cross-over management]. |
|
[Letter on the article: "Kidney and HIV infection"] |
|
Letter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction |
|
Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens |
|
Lymphadenopathy and proteinuria |
|
Lymphopenia in Wegener’s Granulomatosis |
|
Malaria prophylaxis in patients with renal impairment: a review |
|
[Management of targeted therapies in hemodialysis patients]. |
|
[Non-iodinated contrast media nephrotoxicity] |
|
Onco-nephrology: Core Curriculum 2015 |
|
Oncologie & rein |
|
Ostéonécrose mandibulaire et bisphosphonates : état actuel et perspectives |
|
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? |
|
Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure |
|
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis |
|
Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency |
|
Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study |
|
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. |
|
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care |
|
Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients |
|
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia |
|
Relations concentration-effet d'un inhibiteur des récepteurs de type I de l'angiotensine II après administration chez des sujets volontaires sains |
|
Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety |
|
Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network |
|
[Renal insufficiency and breast cancer] |
|
Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency |
|
Renal safety of tenofovir in HIV treatment-experienced patients. |
|
Renal Tubular Drug Transporters |
|
[Renovascular effects of antiangiogenic drugs]. |
|
Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria |
|
[Reply to the article Non-VKA oral anticoagulants: an update for the clinical biologists] |
|
Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. |
|
Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis |
|
Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. |
|
Risk of cancer in patients following chronic dialysis and kidney graft |
|
Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis |
|
Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant |
|
Thrombocytopenia induced by nicotinamide in hemodialysis patients |
|
Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient |
|
Topiramate-induced renal tubular acidosis |
|
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy |
|
Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted |
|
[Treatments of metastases in cancer] |
|
Urologie |
|
Using the right MDRD equation. |
|
Valoración de trastuzumab subcutáneo : una nueva formulación que cumple las necesidades clínicas |
|
Why is a shrunken bladder and a nephrotic kidney an expression of the same disease? |
|